Reactivation of Viral Hepatitis B in Renal Transplant Patients: A Case Report

Abi R1*, Elannaz H1, Khayar Y1, Elkhayat Y1, Bahadi M2, Elkochri S1, Tagajdid MR3 and Amine IL1

1Department of Virology, Mohammed V University, Morocco
2Department of Transplant, Mohammed V University, Morocco
3Department of Virology, Medicine and pharmacy, Sidi Mohamed Ben Abdallah University, Morocco

Abstract

Hepatitis B virus is a chronic infection that affects immune system of host, and is fatal because of reactivation potential due to viral genome HBV. In this case study we discussed about a 65 years old male patient received prolonged immunosuppression therapy emphasized on risk factors and the mechanisms which induces the reactivation of HBV and helps to understand and quantify the risk of HBV reactivation and its consequences.

We report an observation of an immunodeficient patient in whom viral B reactivation occurred one year after renal transplantation.

Keywords: Reactivation of viral hepatitis B; Renal transplant patients; Immunosuppression

Introduction

Hepatitis B Virus (HBV) reactivation is defined as the increase in viremia (>1 log10 IU/ml) in a known patient with chronic or HBV-resolved infection. Since Covalently Closed Circular Deoxyribonucleic Acid (cccDNA) is not removed from the hepatocytes, any event affecting the immune status promotes viral reactivation, sometimes severe or even fatal.

Serological profiles combining significant titles of anti-HBs and anti-HBc antibodies have long been considered as serological scars indicating a former HBC viral hepatitis. However, the development of PCR techniques has revealed the persistence of the Hepatitis B genome (HBV), which is a potential source of viral reactivation.

Case Presentation

Male patient aged 65, followed since 2005 for renal failure in the Nephrology department. In 2010; the patient had received a kidney transplant. A pre-transplant assessment revealed a level of anti-HBs Antibody at 50 IU/ml associated with HBc Ab's defining post-contact immunization against HBV.

One year after the kidney transplant, during which the patient has received immunosuppressive treatment, the evolution was marked by the appearance of hepatic cytolysis (ALAT: 230UI/ml). The markers of acute hepatitis A (anti-HAV IgM), hepatitis E (anti-HEV IgM) and hepatitis C were negatives. Acute infection or reactivation of Herpesviridae (cytomegalovirus, Epstein-Barr virus, varicella-zoster virus, and Herpes simplex virus) has been eliminated. In contrast, the serology confirmed the diagnosis of active viral hepatitis B (positive HBs antigen and anti-HBc antibodies) with high viral replication confirmed by quantification of viral DNA using real-time PCR COBAS® AmpliPrep/COBAS® TaqMan® HBV (8.45 log IU/ml; 284,000,000 IU/ml). The antigen and anti-hepatitis Delta antibody were negative. The diagnosis of reactivation of the hepatitis B virus in relation to immunosuppression was retained; the patient was put under Entecavir. The evolution was marked by a rapid biological response with undetectable viral DNA.

Discussion

HBV reactivation can be classified into two broad categories based on the initial serologic profile: reactivation of HBV in patients who are positive for Hepatitis B Surface Antigen (HBsAg) in serum with or without the presence of HBV DNA. The reverse seroconversion is defined as the reappearance of viral DNA and HBsAg in an individual’s serum, which was initially negative for
both before immunosuppression.

The HBV reactivation may be variable depending on the status of the host, the underlying disease, and the type of immunosuppressive therapy [1]. This can occur either early in the first two weeks after the beginning of chemotherapy or more than one year after the end of immunosuppressive therapy [2]. Understanding the risk factors and the mechanisms that may induce the reactivation of HBV helps certainly to understand and quantify the risk of HBV reactivation and its consequences [3].

The grafted patient has multiple risk factors favoring the development of active hepatitis B: transfusion contamination, transmission by a chronic carrier donor of HBV, or reactivation of a latent B virus in an asymptomatic carrier or in a patient who is nevertheless immunized as in our observation [4].

It is, therefore, necessary to evaluate the infectious risk due to ciclosporin and corticosteroids that these patients receive after the transplant, which may decrease the immune reaction of the body. As in our observation, it is only at the time of the immune rebound at the end of the intense and prolonged immunosuppressive treatment, that hepatitis has manifest itself, sometimes dramatically considering a large number of infected hepatocytes [5].

This immune revival can sometimes lead to the elimination of the virus, but in other cases, such as in our case, the selection pressure may favor the appearance of a mutated B virus in the pre-C region [1,5].

These reactivations are potentially serious: risk of fulminant hepatitis, cirrhosis or even death, increased risk of veno-occlusive disease or graft vs. host disease, but the evolution is most often favorable with even cases of spontaneous elimination of the virus despite the immunosuppression context [6].

The management of HBV reactivation is centered on the likelihood of the risk of reactivation based on the risk factor profile of an individual patient [7]. All patients who are either at high or moderate risk of HBV reactivation should be considered candidates for prophylactic anti-HBV therapy. Usually, we recommend starting anti-HBV therapy before starting immune-suppressive therapy and a baseline complete metabolic profile, complete blood count, prothrombin time, and serum HBV-DNA levels are recommended [8]. It is important to evaluate if the patient has chronic hepatitis B and should be a candidate for the treatment of CHB based on serum ALT level, AST level, albumin level, platelet count, and other laboratory parameters and physical examination [9]. In endemic areas, if a patient presents with increased ALT level in the setting of immunosuppressive therapies, it is prudent to consider checking for serum HBV DNA. We also recommend routine monitoring with the earlier-described tests every three months while on anti-HBV therapy. Consideration of referral to either hepatology or infectious disease specialist before cancer chemotherapy in those at risk of hepatitis B reactivation is recommended [10].

**Conclusion**

Prevention after transplantation in a patient with positive anti-HBs and anti-HBc antibodies requires regular monitoring of the anti-HBs Ab title. In case of a significant decrease of this one, several approaches can be discussed: active immunization by vaccination [2-10], passive immunization by regular injection of specific anti-HBs immunoglobulins, or daily oral administration of antivirals capable of inhibiting the replication viral [2].

**References**